Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis

Journal of Hypertension

Volumn 32, Issue 5, 2014, Pages 1121-1131

  Perlini, Stefano ^a   Salinaro, Francesco ^a   Musca, Francesco ^a   Mussinelli, Roberta ^a   Boldrini, Michele ^a   Raimondi, Ambra ^a   Milani, Paolo ^a   Foli, Andrea ^a   Cappelli, Francesco ^b   Perfetto, Federico ^c   Palladini, Giovanni ^a   Rapezzi, Claudio ^d   Merlini, Giampaolo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Intensive Cardiac Care Unit   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

amyloidosis; midwall fractional shortening; prognosis; systolic function

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; TROPONIN I;

ADULT; AGED; ARTICLE; BLOOD VESSEL WALL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART AMYLOIDOSIS; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE OVERLOAD; HEART LIGHT CHAIN AMYLOIDOSIS; HUMAN; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MIDWALL FRACTIONAL SHORTENING; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; SURVIVAL; AMYLOIDOSIS; ECHOCARDIOGRAPHY; HEART; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; SYSTOLE;

AGED; AMYLOIDOSIS; ECHOCARDIOGRAPHY; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SYSTOLE;

EID: 84898406800     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000120     Document Type: Article

References (63)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349:583-596.
2. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112:2047-2060.
3. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32:45-59.
4. Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998; 91:141-157.
5. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009; 120:1203-1212.
6. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006; 108:2520-2530.
7. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19:1550-1558.
8. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis 2010; 52:347-361.
9. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28:2539-2550.
10. de Simone G, Devereux RB, Celentano A, Roman MJ. Left ventricular chamber and wall mechanics in the presence of concentric geometry. J Hypertens 1999; 17:1001-1006.
11. Shimizu G, Hirota Y, Kita Y, Kawamura K, Saito T, Gaasch WH. Left ventricular midwall mechanics in systemic arterial hypertension. Myocardial function is depressed in pressure-overload hypertrophy. Circulation 1991; 83:1676-1684.
12. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, et al. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol 1994; 23:1444-1451.
13. de Simone G, Devereux RB. Rationale of echocardiographic assessment of left ventricular wall stress and midwall mechanics in hypertensive heart disease. Eur J Echocardiogr 2002; 3:192-198.
14. Gaasch WH, Zile MR, Hoshino PK, Apstein CS, Blaustein AS. Stressshortening relations and myocardial blood flow in compensated and failing canine hearts with pressure-overload hypertrophy. Circulation 1989; 79:872-883.
15. de Simone G, Devereux RB, Koren MJ, Mensah GA, Casale PN, Laragh JH. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation 1996; 93:259-265.
16. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79:319-328.
17. Gertz MA, Merlini G. Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid 2010; 17:48-49.
18. Palladini G, Perlini S, Merlini G. Imaging of systemic amyloidosis. In: Gertz MA, Rajkuma SV, editors. Amyloidosis: diagnosis and treatment. New York: Humana Press; 2010. pp. 15-32.
19. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107:2440-2445.
20. Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NTproBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 2010; 116:3426-3430.
21. Palladini G, Foli A, Milani P, Russo P, Albertini R, Lavatelli F, et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol 2012; 87:465-471.
22. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22:3751-3757.
23. Perlini S, Salinaro F, Cappelli F, Perfetto F, Bergesio F, Alogna A, et al. Prognostic value of fragmented QRS in cardiac AL amyloidosis. Int J Cardiol 2013; 167:2156-2161.
24. Boldrini M, Salinaro F, Mussinelli R, Raimondi A, Alogna A, Musca F, et al. Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis. Ann Noninvasive Electrocardiol 2013; 18:327-335.
25. Mussinelli R, Salinaro F, Alogna A, Boldrini M, Raimondi A, Musca F, et al. Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. Ann Noninvasive Electrocardiol 2013; 18:271-280.
26. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7:79-108.
27. Mondillo S, Galderisi M, Ballo P, Marino PN. Left ventricular systolic longitudinal function: comparison among simple M-mode, pulsed, and M-mode color tissue Doppler of mitral annulus in healthy individuals. J Am Soc Echocardiogr 2006; 19:1085-1091.
28. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10:165-193.
29. Shimizu G, Zile MR, Blaustein AS, Gaasch WH. Left ventricular chamber filling and midwall fiber lengthening in patients with left ventricular hypertrophy: overestimation of fiber velocities by conventional midwall measurements. Circulation 1985; 71:266-272.
30. Colan SD, Borow KM, Neumann A. Left ventricular end-systolic wall stress-velocity of fiber shortening relation: a load-independent index of myocardial contractility. J Am Coll Cardiol 1984; 4:715-724.
31. Borow KM, Green LH, Grossman W, Braunwald E. Left ventricular endsystolic stress-shortening and stress-length relations in human. Normal values and sensitivity to inotropic state. Am J Cardiol 1982; 50:1301-1308.
32. Ballo P, Quatrini I, Giacomin E, Motto A, Mondillo S. Circumferential versus longitudinal systolic function in patients with hypertension: a nonlinear relation. J Am Soc Echocardiogr 2007; 20:298-306.
33. Rozich JD, Carabello BA, Usher BW, Kratz JM, Bell AE, Zile MR. Mitral valve replacement with and without chordal preservation in patients with chronic mitral regurgitation. Mechanisms for differences in postoperative ejection performance. Circulation 1992; 86:1718-1726.
34. Koyama J, Ray-Sequin PA, Falk RH. Prognostic significance of ultrasound myocardial tissue characterization in patients with cardiac amyloidosis. Circulation 2002; 106:556-561.
35. Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging 2010; 3:333-342.
36. Ghio S, Perlini S, Palladini G, Marsan NA, Faggiano G, Vezzoli M, et al. Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis. Eur J Heart Fail 2007; 9:808-813.
37. Henein MY, Gibson DG. Long axis function in disease. Heart 1999; 81:229-231.
38. Greenbaum RA, Ho SY, Gibson DG, Becker AE, Anderson RH. Left ventricular fibre architecture in man. Br Heart J 1981; 45:248-263.
39. Ballo P, Mondillo S, Galderisi M. Determinants of discrepancy between left ventricular chamber systolic performance and effective myocardial contractility in subjects with hypertension. J Hum Hypertens 2006; 20:701-703.
40. Ballo P, Mondillo S, Guerrini F, Barbati R, Picchi A, Focardi M. Midwall mechanics in physiologic and hypertensive concentric hypertrophy. J Am Soc Echocardiogr 2004; 17:418-427.
41. Aurigemma GP, Silver KH, McLaughlin M, Mauser J, Gaasch WH. Impact of chamber geometry and gender on left ventricular systolic function in patients >60 years of age with aortic stenosis. Am J Cardiol 1994; 74:794-798.
42. Aurigemma GP, Silver KH, Priest MA, Gaasch WH. Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol 1995; 26:195-202.
43. Aurigemma GP, Williams D, Gaasch WH, Reda DJ, Materson BJ, Gottdiener JS. Ventricular and myocardial function following treatment of hypertension. Am J Cardiol 2001; 87:732-736.
44. Perlini S, Muiesan ML, Cuspidi C, Sampieri L, Trimarco B, Aurigemma GP, et al. Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry. Circulation 2001; 103:678-683.
45. De Simone G, Devereux RB, Volpe M, Camargo MJ, Wallerson DC, Laragh JH. Midwall LV mechanics in rats with or without renovascular hypertension: effect of different Na+ intakes. Am J Physiol 1996; 270:H628-H637.
46. Norton GR, Woodiwiss AJ, Gaasch WH, Mela T, Chung ES, Aurigemma GP, et al. Heart failure in pressure overload hypertrophy. The relative roles of ventricular remodeling and myocardial dysfunction. J Am Coll Cardiol 2002; 39:664-671.
47. Chung ES, Perlini S, Aurigemma GP, Fenton RA, Dobson JG Jr, Meyer TE. Effects of chronic adenosine uptake blockade on adrenergic responsiveness and left ventricular chamber function in pressure overload hypertrophy in the rat. J Hypertens 1998; 16:1813-1822.
48. Perlini S, Ferrero I, Palladini G, Tozzi R, Gatti C, Vezzoli M, et al. Survival benefits of different antiadrenergic interventions in pressure overload left ventricular hypertrophy/failure. Hypertension 2006; 48:93-97.
49. Perlini S, Chung ES, Aurigemma GP, Meyer TE. Alterations in early filling dynamics predict the progression of compensated pressure overload hypertrophy to heart failure better than abnormalities in midwall systolic shortening. Clin Exp Hypertens 2013; 35:401-411.
50. Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001; 104:1594-1597.
51. Falk RH. Cardiac amyloidosis: a treatable disease, often overlooked. Circulation 2011; 124:1079-1085.
52. Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004; 94:1008-1010.
53. Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a noncanonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A 2010; 107:4188-4193.
54. Aurigemma GP, Gaasch WH, McLaughlin M, McGinn R, Sweeney A, Meyer TE. Reduced left ventricular systolic pump performance and depressed myocardial contractile function in patients >65 years of age with normal ejection fraction and a high relative wall thickness. Am J Cardiol 1995; 76:702-705.
55. Perugini E, Rapezzi C, Reggiani LB, Poole-Wilson P, Branzi A, Henein MY. Comparison of ventricular long-axis function in patients with cardiac amyloidosis versus idiopathic restrictive cardiomyopathy. Am J Cardiol 2005; 95:146-149.
56. Koyama J, Davidoff R, Falk RH. Longitudinal myocardial velocity gradient derived from pulsed Doppler tissue imaging in AL amyloidosis: a sensitive indicator of systolic and diastolic dysfunction. J Am Soc Echocardiogr 2004; 17:36-44.
57. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 2003; 107:2446-2452.
58. Bellavia D, Abraham TP, Pellikka PA, Al-Zahrani GB, Dispenzieri A, Oh JK, et al. Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. J Am Soc Echocardiogr 2007; 20:1194-1202.
59. Cappelli F, Porciani MC, Bergesio F, Perfetto F, De Antoniis F, Cania A, et al. Characteristics of left ventricular rotational mechanics in patients with systemic amyloidosis, systemic hypertension and normal left ventricular mass. Clin Physiol Funct Imaging 2011; 31:159-165.
60. Perlini S. Determinants of left ventricular mass in hypertensive heart disease: a complex interplay between volume, pressure, systolic function and genes. J Hypertens 2007; 25:1341-1342.
61. Guan J, Mishra S, Shi J, Plovie E, Qiu Y, Cao X, et al. Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Res Cardiol 2013; 108:378.
62. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30:989-995.
63. Buss SJ, Emami M, Mereles D, Korosoglou G, Kristen AV, Voss A, et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J Am Coll Cardiol 2012; 60:1067-1076.